Neurocrine Biosciences Director George Morrow Files Form 144 to Sell $2.15M in Stock

Transaction Overview

George Morrow, a member of the Board of Directors of Neurocrine Biosciences, Inc., submitted a Form 144 filing on November 2, 2026, indicating a proposed sale of 14,700 common shares. The aggregate market value of the shares to be sold is $2,147,670.00, implying a sale price of approximately $146.10 per share.

Origin of Securities & Trading Plan

• Acquisition Method: The 14,700 shares are being acquired through the exercise of stock options from the issuer, paid for in cash on November 2, 2026.
• Rule 10b5-1 Trading Plan: The transaction is governed by a Rule 10b5-1 trading plan adopted on May 26, 2026.
• Prior Transactions: In the preceding three months, the insider executed a sale of 300 shares on October 30, 2026, generating gross proceeds of $44,700.00 under the same 10b5-1 plan.
• Broker: Morgan Stanley Smith Barney LLC Executive Financial Services.

Market Impact & Significance

• Dilution / Float Context: The 14,700 shares represent approximately 0.014% of the company's 101,649,181 outstanding common shares, presenting negligible dilution or market overhang.
• Significance Rating: Low. The disposition constitutes an option exercise and sale conducted under a predetermined Rule 10b5-1 trading plan, indicating routine portfolio diversification rather than a discretionary signal on company outlook.